page_title: CAPOX
hierarchical_section_title: CAPOX
caption_attribution_description: English: Figure-2 A case with locallyadvanced rectal cancer treated with neoadjuvant chemotherapywith an oxaliplatin-based regimen Tumor reduction of 30% and a longer distance on the anal side without severe adverse events were achieved after this treatment. Consequently, laparoscopic curative resection with anal preservation was achieved because of effective chemotherapy before surgery. Pre-treatment findings: T3 N1 M0 cStage IIIa, XELOX therapy: 4 courses, Operation: Laparoscopic intersphincter resection+ bilateral lymph node dissection, Pathological findings: tub2 ypT1b/SM ly0 v0 N0 (0/25) ypStageⅠ 6), Pathological response: Grade 1b 6) (Watanabe T, Muro K, et al: Int J Clin Oncol, 2018; 23: 1-34 6))
context_page_description: CAPOX is a chemotherapy regimen consisting of capecitabine combined with oxaliplatin.
  Xelox regime operates in 3-week cycles, usually with 8 cycles in total; Xeloda is orally taken for twice daily for two weeks, while oxaliplatin is administrated by IV on the first day of the cycle; there is a one-week rest period before the next cycle.
context_section_description: CAPOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.
  Xelox regime operates in 3-week cycles, usually with 8 cycles in total; Xeloda is orally taken for twice daily for two weeks, while oxaliplatin is administrated by IV on the first day of the cycle; there is a one-week rest period before the next cycle.
caption: Pre- and post-chemotherapy images of a T3 N1 M0 cStage IIIa colorectal cancer. Four courses of CAPOX therapy.
exif: {}